Asher Kornbluth, MD
Mount Sinai School of Medicine
New York, NY

Asher A. Kornbluth, MD
Clinical Professor of Medicine
The Inflammatory Bowel Disease Center
The Henry D. Janowitz Division of Gastroenterology
Mount Sinai School of Medicine
New York, New York

Asher A. Kornbluth received a medical degree from Downstate Medical Center in New York and completed his postgraduate training in Internal Medicine as both resident and Chief Resident at the Albert Einstein College of Medicine in the Bronx. He was a Gastroenterology fellow at Mount Sinai Hospital Medical Center in New York City.

A Diplomate of the National Board of Medical Examiners and the American Board of Internal Medicine (in both Internal Medicine and Gastroenterology), Dr. Kornbluth holds membership in the American Gastroenterological Association, the American College of Gastroenterology (ACG), the American Society of Gastroenterology Endoscopy, and the Alpha Omega Alpha Honor Medical Society—for which he was selected as both an honored educator and an honored clinician. He has received numerous awards as a medical educator, including the Teacher of the Year for six consecutive years at the Mount Sinai School of Medicine. He was also selected by the Mount Sinai graduating class for two consecutive years to lead the class in their graduation vows, followed by selection as Grand Marshall at the graduation Commencement. In 2009, he was awarded the William Dock Lifetime Master Teacher Award in Medicine by the Downstate Medical Center of the State University of New York.

Dr. Kornbluth has published more than 100 articles, abstracts, and book chapters and is the principal author of all 3 editions of the Ulcerative Colitis Practice Guidelines in Adults, published by the ACG Practice Parameters Committee. He has published in, and is a reviewer for, many peer-reviewed journals, including The New England Journal of Medicine, Gastroenterology, Annals of Internal Medicine, American Journal of Gastroenterology, Clinical Gastroenterology and Hepatology, Inflammatory Bowel Diseases, Journal of Clinical Gastroenterology, Alimentary Pharmacology and Therapeutics, and he serves as Associate Editor for Inflammatory Bowel Diseases. Currently, he is a principal investigator on a number of clinical trials examining new therapeutic agents in inflammatory bowel disease, as well as investigations involving new diagnostic methods, responses to medical therapy and the natural history of inflammatory bowel disease. As an educator, Dr. Kornbluth has taught and lectured extensively in the United States and internationally, and he is the founder and annual course director of the Mt. Sinai IBD Consultants Course.

The Icahn School of Medicine at Mount Sinai

Mount Sinai has been on the forefront of research, identification, and treatment of gastrointestinal illness since the division's early days. In the first part of the 20th Century, gastric secretion and duodenal contents were studied with the use of Rehfus tubes. An outpatient clinic was founded and devoted solely to GI diseases in 1913.

Key Researchers
Some of the key researchers of that era, including Drs. A.A. Berg, Burrill Crohn, Eli Moschcowitz, Leon Ginzburg, Ralph Colp, Percy Klingenstein, and Gordon Oppenheimer, gave their medical and surgical services to Mount Sinai. In 1920, Drs. Eli Moschcowitz and A.O. Wilensky published a clinical and pathological study of intestinal granulomas.

Research Venues
Mount Sinai was the source of the seminal paper in 1932 by Drs. Crohn, Ginzburg, and Oppenheimer describing "regional ileitis." Dr. A.A. Berg, a disciple of Dr. Henry Billroth, perfected the subtotal gastrectomy for the treatment of peptic ulcer. In 1933, the drip treatment for peptic ulcer was described by Dr. Asher Winkelstein. 1936 saw the establishment of a dedicated research laboratory for the study of gastric secretions by Dr. Franklin Hollander, who originated the Hollander Test for completeness of vagotomy.

Understanding Gastroenterological Problems
Stimulated by rapid technological advances, important new understanding of and approaches to gastroenterological problems burgeoned in the middle of the century. Drs. Hans Popper and Fenton Schaffner made great discoveries that expanded our knowledge of cirrhosis and hepatitis. Drs. Bernard Wolf and Richard Marshak elucidated the radiological changes in esophagitis, hiatal hernia, and inflammatory bowel disease.

Results-Oriented Research
Dr. John Garlock perfected the surgery of esophageal malignancy and inflammatory bowel disease. Dr. Henry Janowitz contributed to our understanding of peptic ulcer, elucidated the natural history of inflammatory bowel disorders, and together with Dr. David Dreiling, studied pancreatic secretion in the normal and diseased states. The important role of immunosuppressive therapy in inflammatory bowel disease was defined by Drs. Daniel Present and Burton Korelitz. Dr. Jerome Waye pioneered and perfected the use of GI endoscopy without fluoroscopy, making colonoscopy a practical tool for every gastroenterologist. A recent list of the top 50 most influential gastroenterology professionals of the 20th Century included six individuals from Mount Sinai — more than any other institution in the nation.

Fellowship Training
In 1958, the National Institutes of Health recognized the importance of Mount Sinai as a research center with a grant for gastroenterology fellowship training. This prestigious grant was re-awarded in 2000 as a combined GI/Liver training grant, making Mount Sinai currently the only medical school in the New York metropolitan area with this award.

Division Directors
In 1983, Dr. David Sachar assumed directorship of the division from Dr. Henry Janowitz, whose 25 years of leadership were honored by the endowment of the division in his name. Dr. Sachar has made important contributions to the diagnosis and classification of Crohn's disease and helped to define the neoplastic complications of inflammatory bowel disease. In 1993, Dr. Sachar was named the first Dr. Burrill B. Crohn Professor of Medicine. This chair was transferred to Dr. Steven Itzkowitz in 1999 when he became the Director of the division. In November 2003, Dr. Lloyd Mayer became Chief of the division. Bruce Sands, MD, MPH has assumed the role of Chief of the Division in July 2010.

 Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.

 Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.

 Clinical presentation and outcomes of inflammatory bowel disease patients admitted to the intensive care unit.

 The effect of intravenous cyclosporine on rates of colonic surgery in hospitalized patients with severe Crohn's colitis.

 Double balloon enteroscopy in Crohn's disease: background and current state of play.

 Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population.

 Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis (OCTAVE)

This study is an open label, long-term extension study for subjects with moderate to severe ulcerative colitis designed to evaluate long term therapy of CP-690,550.

Estimated Enrollment: 725
Study Start Date: October 2012
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: March 2018 (Final data collection date for primary outcome measure)

 B0151005 Open-Label Extension Study (ANDANTE II)

This is a multi-center Phase 2, open label, safety extension study in subjects with moderate to severe CD who are anti-TNF inadequate responders. Subjects eligible for this study will have completed the 12-week induction period of study B0151003 and will be enrolled as either responders or non responders.

Estimated Enrollment: 180
Study Start Date: June 2011
Estimated Study Completion Date: March 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)

    Webcasts

    Impact of IBD on Healthcare Systems

    Gary Lichtenstein, MD ; David Rubin, MD ; Bruce Sands, MD ; Brennan Spiegel, MD ; Douglas Wolf, MD

    Didactic Lecture

    view details >

    eMonograph

    GI Alliance Payer Summit

    view details >

    Clinical and Managed Care Perspectives in Inflammatory Bowel Disease: Closing the Gap

    view details >

    Addressing Health Outcomes and Rising Costs in the Management of Inflammatory Bowel Disease

    view details >

    The Guide to Guidelines in IBD: Interpretation and Appropriate Use in Clinical Practice

    view details >

    INFORM UC: An Update on Contemporary Management of UC

    view details >

    Breaking The Barriers: Improving Access to Biologic Therapies in IBD

    view details >

    IBD Management: State of the Art in 2018

    view details >

    Improving IBD Care A Personalized Approach to Management

    view details >

    Expert Perspectives in the Management of Inflammatory Bowel Disease (IBD): A Review of Recent Advances

    view details >

    Advances in IBD

    view details >

    Optimizing the Management of Inflammatory Bowel Disease

    view details >

    Webcasts

    Impact of IBD on Healthcare Systems

    Gary Lichtenstein, MD ; David Rubin, MD ; Bruce Sands, MD ; Brennan Spiegel, MD ; Douglas Wolf, MD

    Didactic Lecture

    view details >

    Dinner Meetings

    Content available soon

    Audiocasts

    Content available soon!

    Content available soon!

    © Copyright 2013-2024 GI Health Foundation. All rights reserved.
    This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.